Network meta-analyses comparing the efficacy of biologic treatments for achieving complete resolution of nail psoriasis at 24–28 and 48–52 weeks
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Network meta-analyses comparing the efficacy of biologic treatments for achieving complete resolution of nail psoriasis at 24–28 and 48–52 weeks
Authors
Keywords
-
Journal
JOURNAL OF DERMATOLOGICAL TREATMENT
Volume 34, Issue 1, Pages -
Publisher
Informa UK Limited
Online
2023-10-02
DOI
10.1080/09546634.2023.2263108
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Bayesian network meta-analysis of head-to-head trials for complete resolution of nail psoriasis
- (2023) Husein Husein-ElAhmed et al. CLINICAL AND EXPERIMENTAL DERMATOLOGY
- Effects of risankizumab on nail psoriasis in patients with active psoriatic arthritis: results from KEEPsAKE 1
- (2022) L.E. Kristensen et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Efficacy of Tildrakizumab for the Treatment of Difficult-to-Treat Areas: Scalp, Nail, Palmoplantar and Genital Psoriasis
- (2022) Marco Galluzzo et al. Journal of Clinical Medicine
- Sustained Resolution of Nail Psoriasis Through 5 Years with Ixekizumab: A Post-Hoc analysis from UNCOVER-3
- (2022) Alexander Egeberg et al. ACTA DERMATO-VENEREOLOGICA
- Small molecule inhibitors and biologics in treating nail psoriasis: a systematic review and network meta-analysis
- (2021) I-Hsin Huang et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Network meta-analysis comparing the efficacy of biologic treatments for achieving complete resolution of nail psoriasis
- (2021) Kristian Reich et al. JOURNAL OF DERMATOLOGICAL TREATMENT
- Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial
- (2021) Kristian Reich et al. LANCET
- Bimekizumab versus Secukinumab in Plaque Psoriasis
- (2021) Kristian Reich et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy of ixekizumab on nail psoriasis in paediatric patients with moderate‐to‐severe psoriasis: a post hoc analysis from IXORA‐PEDS
- (2021) M.M.B. Seyger et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- In psoriasis treatment, greater improvement in skin severity predicts greater improvement in nail severity
- (2020) Amanda M. Rusk et al. JOURNAL OF DERMATOLOGICAL TREATMENT
- Efficacy of brodalumab in the treatment of scalp and nail psoriasis: results from three phase 3 trials
- (2020) Boni Elewski et al. JOURNAL OF DERMATOLOGICAL TREATMENT
- Ixekizumab and Ustekinumab Efficacy in Nail Psoriasis in Patients with Moderate-to-Severe Psoriasis: 52-Week Results from a Phase 3, Head-to-Head Study (IXORA-S)
- (2020) Norman Wasel et al. Dermatology and Therapy
- Multicentre, randomised, open-label, parallel-group study evaluating the efficacy and safety of ixekizumab versus adalimumab in patients with psoriatic arthritis naïve to biological disease-modifying antirheumatic drug: final results by week 52
- (2020) Josef S Smolen et al. ANNALS OF THE RHEUMATIC DISEASES
- A Head‐to‐Head Comparison of Ixekizumab Versus Guselkumab in Patients with Moderate‐to‐Severe Plaque Psoriasis: 24‐Week Efficacy and Safety Results from a Randomised, Double‐Blinded Trial
- (2020) A. Blauvelt et al. BRITISH JOURNAL OF DERMATOLOGY
- A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial
- (2019) Philip J Mease et al. ANNALS OF THE RHEUMATIC DISEASES
- Rapid Response of Biologic Treatments of Moderate-to-Severe Plaque Psoriasis: A Comprehensive Investigation Using Bayesian and Frequentist Network Meta-analyses
- (2019) Richard B. Warren et al. Dermatology and Therapy
- A head‐to‐head comparison of ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis: 12‐week efficacy, safety and speed of response from a randomized, double‐blinded trial
- (2019) A. Blauvelt et al. BRITISH JOURNAL OF DERMATOLOGY
- Adalimumab for nail psoriasis: Efficacy and safety from the first 26 weeks of a phase 3, randomized, placebo-controlled trial
- (2018) Boni E. Elewski et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Efficacy of Guselkumab Compared With Adalimumab and Placebo for Psoriasis in Specific Body Regions
- (2018) Peter Foley et al. JAMA Dermatology
- Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis
- (2015) Mark Lebwohl et al. NEW ENGLAND JOURNAL OF MEDICINE
- Incidence and clinical predictors of psoriatic arthritis in patients with psoriasis: A population-based study
- (2009) Floranne C. Wilson et al. ARTHRITIS AND RHEUMATISM
- Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during 1 year
- (2007) Phoebe Rich et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started